Trial Profile
A Phase III, Multicentric, Randomized, Open, Comparative Study to Evaluate if the Addition of Recombinant Human Luteinising Hormone [r-hLH (Luveris)] to Follicle Stimulating Hormone (FSH) From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing Assisted Reproduction Technology (ART), Who Required High FSH Dose in a Previous Cycle.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Lutropin alfa (Primary)
- Indications Female infertility
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck KGaA
- 15 Dec 2011 Official Title amended as reported by ClinicalTrials.gov record (NCT01071200).
- 15 Dec 2011 Official Title amended as reported by ClinicalTrials.gov record (NCT01071200).
- 15 Dec 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.